- ¥7440.90 - 10323.90
- 阿拉丁
- 上海
- C651914
- 2026年05月08日
企业认证
相关产品推荐更多 >
![tert-butyl (1S,5S)-3-({5-methyl-6-[(2-methylpyridin-3-yl)oxy]pyrimidin-4-yl}oxy)-8-azabicyclo[3.2.1]octane-8-carboxylate，Moligand™，阿拉丁](https://img1.dxycdn.com/p/s14/2026/0508/225/8465590646146562502.png!wh200)
tert-butyl (1S,5S)-3-({5-methyl-6-[(2-methylpyridin-3-yl)oxy]pyrimidin-4-yl}oxy)-8-azabicyclo[3.2.1]octane-8-carboxylate，Moligand™，阿拉丁
¥3999.90
CV-6209，100488-87-7，≥95%，阿拉丁
¥1600.90
强力霉素，564-25-0，Moligand™, ≥97%，阿拉丁
¥339.90![1-N-[(2S,3R)-3-hydroxy-1-phenyl-4-[[3-(trifluoromethyl)phenyl]methylamino]butan-2-yl]-3-N,5-dimethyl-3-N-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide，Moligand™，阿拉丁](https://img1.dxycdn.com/p/s14/2026/0508/871/2519674332880662502.png!wh200)
1-N-[(2S,3R)-3-hydroxy-1-phenyl-4-[[3-(trifluoromethyl)phenyl]methylamino]butan-2-yl]-3-N,5-dimethyl-3-N-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide，Moligand™，阿拉丁
¥3999.90
BMS-986278，2170126-74-4，Moligand™, ≥99%，阿拉丁
¥329.90
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
细胞污染识别与处理全攻略：5 种常见类型+关键误区Cytoscape 教程来了！快速实现顶刊同款通路网络图五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
-20°C储存；超低温运输
- 英文名：
Carboxypeptidase G2 (CPG2) Inhibitor
- 库存：
期货
- 供应商：
上海阿拉丁生化科技股份有限公司
- CAS号：
192203-60-4
- 规格：
C651914-100mg/C651914-50mg
| 规格： | C651914-100mg | 产品价格： | ¥10323.90 |
|---|---|---|---|
| 规格： | C651914-50mg | 产品价格： | ¥7440.90 |
中文名：Carboxypeptidase G2 (CPG2) Inhibitor
英文名：Carboxypeptidase G2 (CPG2) Inhibitor
纯度：≥98%
货号：C651914
Cas号：192203-60-4
存储温度：-20°C储存
运输条件：超低温运输
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验failure and who are treated using high-dose protocols are often given carboxypeptidase-G2 (CPDG2 ) as a chemoprotective agent. In this setting an inactive metabolite of MTX, 2, 4-diamino-N10 -methylpteroic acid (DAMPA) is produced. DAMPA cross-reacts
Current cancer chemotherapy strategies are often hampered by the lack of tumor selectivity, resulting in unwanted damage to healthy tissue. Gene-directed enzyme-prodrug therapy (GDEPT) (1 ) and virus-directed enzyme-prodrug therapy (VDEPT
Antibody-Directed Enzyme-Prodrug Therapy
optimized molecules for clinical trials. This chapter will start by giving a brief overview of the field, concentrating on the developments in our own department using anti-CEA antibodies and the bacterial enzyme carboxypeptidase G2. This will be followed
技术资料暂无技术资料 索取技术资料
